Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19 (September 2022)
There are many pharmacologic therapies that are being used or considered for treatment of
coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence …
coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence …
The signal pathways and treatment of cytokine storm in COVID-19
L Yang, X **e, Z Tu, J Fu, D Xu, Y Zhou - Signal transduction and …, 2021 - nature.com
Abstract The Coronavirus Disease 2019 (COVID-19) pandemic has become a global crisis
and is more devastating than any other previous infectious disease. It has affected a …
and is more devastating than any other previous infectious disease. It has affected a …
[HTML][HTML] Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …
inflammatory properties. This study evaluates the efficacy and safety of baricitinib in …
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …
Infectious Diseases Society of America Guidelines on the treatment and management of patients with COVID-19 (April 2020)
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …
Tofacitinib in patients hospitalized with Covid-19 pneumonia
PO Guimarães, D Quirk, RH Furtado… - … England Journal of …, 2021 - Mass Medical Soc
Background The efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who
are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear. Methods …
are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear. Methods …
Baricitinib plus remdesivir for hospitalized adults with Covid-19
Abstract Background Severe coronavirus disease 2019 (Covid-19) is associated with
dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus …
dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus …
Drug repurposing approach to fight COVID-19
Currently, there are no treatment options available for the deadly contagious disease,
coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new …
coronavirus disease 2019 (COVID-19). Drug repurposing is a process of identifying new …
Immunopathogenesis and treatment of cytokine storm in COVID-19
JS Kim, JY Lee, JW Yang, KH Lee… - …, 2021 - pmc.ncbi.nlm.nih.gov
Severe coronavirus disease 2019 (COVID-19) is characterized by systemic hyper-
inflammation, acute respiratory distress syndrome, and multiple organ failure. Cytokine …
inflammation, acute respiratory distress syndrome, and multiple organ failure. Cytokine …
Treatment for COVID-19: An overview
Abstract Coronavirus disease 2019 (COVID-19) is an infectious disease caused by
coronavirus-2 (SARS-CoV-2) that causes a severe acute respiratory syndrome, a …
coronavirus-2 (SARS-CoV-2) that causes a severe acute respiratory syndrome, a …